Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Study ID
- NCT04701060
- Phase
- PHASE2
- Status
- Completed
Conditions
- Resectable Hepatocellular Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w — DRUGpreoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
Study Details
This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence
Key Dates
- Start date
- Jan 26, 2021
- Status verified
- Jan 2021
- Primary completion
- Mar 4, 2024
- Completion
- Oct 4, 2024
Study Design
- Enrollment
- 31 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Camrelizumab combined with apatinibpreoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
Primary Outcome Measure
Major Pathological Response [ Time Frame: post-operation ]
Related Studies
- SIRT With Tremelimumab and Durvalumab for Resectable HCCPHASE1 · Recruiting · Jiping Wang, MD, PhD · Los Angeles, California
- THIO and Cadonilimab in Resectable Hepatocellular CarcinomaEARLY_PHASE1 · Not Yet Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas